SGLT inhibitors for Type 1 Diabetes: What to Know

What are SGLT inhibitors? SGLT inhibitors are a class of drugs currently approved for type 2 diabetes; examples include Farxiga, Invokana, and Jardiance.

Click here to learn about this class of diabetes drugs.

 

What about SGLT inhibitors in type 1 diabetes? SGLT inhibitors are not yet approved for type 1 diabetes treatment, but some people with type 1 diabetes have been taking SGLT inhibitors "off-label" (for a use not approved by the FDA or EMA). 

Click here to learn how SGLT inhibitors fit into type 1 diabetes treatment. 

 

What are the benefits of SGLT inhibitors in type 1 diabetes? Promising research shows SGLT inhibitors could improve outcomes for people with type 1 diabetes, including improved time-in-range and A1C and weight reduction.

Click here to read more about this research.

 

What are the risks of SGLT inhibitors in type 1 diabetes? Using SGLT inhibitors in type 1 diabetes increases the risk of diabetic ketoacidosis (DKA), which is a dangerous complication that can become life-threatening if untreated. 

Click here to learn about DKA and here to learn about ketones. Click here to see a helpful infographic about reducing the risks. 

 

What is the news about SGLT inhibitors in type 1 diabetes? SGLT inhibitors for type 1 diabetes are currently under regulatory review.

Click here to read about the SGLT inhibitors under regulatory review. Click here to read about the outcome of a recent FDA Advisory Committee meeting.